Generic Romvimza Availability
Last updated on May 7, 2025.
Romvimza is a brand name of vimseltinib, approved by the FDA in the following formulation(s):
ROMVIMZA (vimseltinib - capsule;oral)
-
Manufacturer: DECIPHERA PHARMS
Approval date: February 14, 2025
Strength(s): 14MG [RLD], 20MG [RLD], 30MG [RLD]
Is there a generic version of Romvimza available?
No. There is currently no therapeutically equivalent version of Romvimza available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Romvimza. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods of treating disorders using CSF1R inhibitors
Patent 11,103,507
Issued: August 31, 2021
Inventor(s): Flynn; Daniel L. et al.
Assignee(s): Deciphera Pharmaceuticals, LLC (Waltham, MA)Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Patent expiration dates:
- February 3, 2040✓
- February 3, 2040
-
Methods of treating disorders using CSF1R inhibitors
Patent 11,679,110
Issued: June 20, 2023
Inventor(s): Flynn; Daniel L. et al.
Assignee(s): Deciphera Pharmaceuticals, LLC (Waltham, MA)Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Patent expiration dates:
- February 3, 2040✓
- February 3, 2040
-
Methods of treating disorders using CSF1R inhibitors
Patent 12,285,430
Issued: April 29, 2025
Inventor(s): Flynn; Daniel L. et al.
Assignee(s): Deciphera Pharmaceuticals, LLC (Waltham, MA)Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).
Patent expiration dates:
- December 23, 2039✓
- December 23, 2039
-
2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities
Patent 9,181,223
Issued: November 10, 2015
Inventor(s): Kaufman; Michael D. et al.
Assignee(s): Deciphera Pharmaceuticals, LLC (Lawrence, KS)Described are compounds of Formula I ##STR00001##
which find utility in the treatment of cancer, autoimmune diseases and metabolic bone disorders through inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. These compounds also find utility in the treatment of other mammalian diseases mediated by c-FMS, c-KIT, or PDGFR kinases.Patent expiration dates:
- March 14, 2034✓✓
- March 14, 2034
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- February 14, 2030 - NEW CHEMICAL ENTITY
More about Romvimza (vimseltinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: miscellaneous antineoplastics
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.